BioCentury | Jan 8, 2021
Emerging Company Profile

Co-founded by Mukherjee and Vale, Myeloid is directing monocytes against cancer

...the company could have readouts in 1H22, co-founder and CEO Daniel Getts told BioCentury. He was VP of research at TCR2 Therapeutics Inc....
BioCentury | Jan 8, 2021
Deals

ArsenalBio reaches next stage of maturity with BMS deal

...site.And unlike the handful of other companies doing targeting integration, such as Pact Pharma Inc.and TCR2 Therapeutics Inc....
BioCentury | Nov 18, 2020
Emerging Company Profile

Led by ElevateBio’s Finer, LifeEDIT is pursuing novel enzymes for gene editing

...manufacturing partnerships with Massachusetts General Hospital and TCR2 Therapeutics Inc....
BioCentury | Nov 13, 2020
Deals

Nov. 12 Quick Takes: MorphoSys, UCB bring in new tech via deals; plus Cevec-Roche, Bridge-BI, Affimed-Roivant, Insilico-J&J, TCR2-ElevateBio

...& Johnson Innovation – JLABS. TCR2 heads to BaseCamp Via a manufacturing partnership with ElevateBio LLC, TCR2 Therapeutics Inc....
...gene therapy.TargetsENPP2 (ATX) - autotaxin BC Staff BBT-877 Affimed Roivant Sciences Insilico Medicine Inc. Johnson & Johnson Bridge Biotherapeutics Boehringer Ingelheim Cevec Pharmaceuticals GmbH MorphoSys ElevateBio LLC TCR2 Therapeutics Cherry...
BioCentury | Jul 28, 2020
Product Development

TCR2 gains on first signs of cell therapy efficacy in solid tumors

...at Monday’s closing price, TCR2 would raise $98 million. Targets MSLN - Mesothelin Lauren Martz, Senior Editor TC-210 TCR2 Therapeutics Inc. Mesothelin...
BioCentury | May 29, 2020
Management Tracks

Delaney takes over as Assembly’s CSO; plus NGM, TCR2, Amunix, Evox, Vor and more

...13. She was president and CFO of Castlight Health Inc. (NYSE:CSLT). T cell therapy company TCR2 Therapeutics Inc....
...She was SVP and CFO of Pfenex Inc. (NYSE-A:PFNX). Robin Sawka, Staff Writer Assembly Biosciences Inc. NGM Biopharmaceuticals Inc. TCR2 Therapeutics Inc. Amunix...
BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

...VP and general manager of global oncology at Amgen Inc. (NASDAQ:AMGN). T cell therapy company TCR2 Therapeutics Inc....
...president and CEO of Arianne Clinical Research Inc. Robin Sawka, BioCentury Staff PTC Therapeutics Inc. uniQure N.V. Sangamo BioSciences Inc. TCR2 Therapeutics Inc. Five...
BioCentury | Aug 10, 2019
Company News

Management tracks: Melinta, Editas, Accelerate, Santhera

...Revance Therapeutics Inc. (Newark, Calif.) and BlackThorn Therapeutics Inc. (San Francisco, Calif.) T-cell therapy company TCR2 Therapeutics...
...Inc. Aravive Inc. Editas Medicine Inc. Emalex Biosciences Inc. JMP Securities Melinta Therapeutics Inc. Molecular Partners AG Palladio Biosciences Inc. Santhera Pharmaceuticals Holding AG TCR2 Therapeutics Inc....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:HOTH) 2/15/19 $7.0 $52.8 $55.8 6% Stealth BioTherapeutics Corp. (NASDAQ:MITO) 2/14/19 $85.1 $420.4 $437.9 4% TCR2 Therapeutics Inc....
BioCentury | Jun 7, 2019
Finance

Alexandria parlays growing life sciences real estate holdings into a flurry of VC deals

...LLC in July 2018; the $125 million series B round for T cell therapy play TCR2 Therapeutics Inc....
...Precision BioSciences Inc., Durham, N.C. Relay Therapeutics Inc., Cambridge, Mass. Roche (SIX:ROG; OTCQB:RHHBY), Basel, Switzerland TCR2 Therapeutics Inc....
Items per page:
1 - 10 of 42
BioCentury | Jan 8, 2021
Emerging Company Profile

Co-founded by Mukherjee and Vale, Myeloid is directing monocytes against cancer

...the company could have readouts in 1H22, co-founder and CEO Daniel Getts told BioCentury. He was VP of research at TCR2 Therapeutics Inc....
BioCentury | Jan 8, 2021
Deals

ArsenalBio reaches next stage of maturity with BMS deal

...site.And unlike the handful of other companies doing targeting integration, such as Pact Pharma Inc.and TCR2 Therapeutics Inc....
BioCentury | Nov 18, 2020
Emerging Company Profile

Led by ElevateBio’s Finer, LifeEDIT is pursuing novel enzymes for gene editing

...manufacturing partnerships with Massachusetts General Hospital and TCR2 Therapeutics Inc....
BioCentury | Nov 13, 2020
Deals

Nov. 12 Quick Takes: MorphoSys, UCB bring in new tech via deals; plus Cevec-Roche, Bridge-BI, Affimed-Roivant, Insilico-J&J, TCR2-ElevateBio

...& Johnson Innovation – JLABS. TCR2 heads to BaseCamp Via a manufacturing partnership with ElevateBio LLC, TCR2 Therapeutics Inc....
...gene therapy.TargetsENPP2 (ATX) - autotaxin BC Staff BBT-877 Affimed Roivant Sciences Insilico Medicine Inc. Johnson & Johnson Bridge Biotherapeutics Boehringer Ingelheim Cevec Pharmaceuticals GmbH MorphoSys ElevateBio LLC TCR2 Therapeutics Cherry...
BioCentury | Jul 28, 2020
Product Development

TCR2 gains on first signs of cell therapy efficacy in solid tumors

...at Monday’s closing price, TCR2 would raise $98 million. Targets MSLN - Mesothelin Lauren Martz, Senior Editor TC-210 TCR2 Therapeutics Inc. Mesothelin...
BioCentury | May 29, 2020
Management Tracks

Delaney takes over as Assembly’s CSO; plus NGM, TCR2, Amunix, Evox, Vor and more

...13. She was president and CFO of Castlight Health Inc. (NYSE:CSLT). T cell therapy company TCR2 Therapeutics Inc....
...She was SVP and CFO of Pfenex Inc. (NYSE-A:PFNX). Robin Sawka, Staff Writer Assembly Biosciences Inc. NGM Biopharmaceuticals Inc. TCR2 Therapeutics Inc. Amunix...
BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

...VP and general manager of global oncology at Amgen Inc. (NASDAQ:AMGN). T cell therapy company TCR2 Therapeutics Inc....
...president and CEO of Arianne Clinical Research Inc. Robin Sawka, BioCentury Staff PTC Therapeutics Inc. uniQure N.V. Sangamo BioSciences Inc. TCR2 Therapeutics Inc. Five...
BioCentury | Aug 10, 2019
Company News

Management tracks: Melinta, Editas, Accelerate, Santhera

...Revance Therapeutics Inc. (Newark, Calif.) and BlackThorn Therapeutics Inc. (San Francisco, Calif.) T-cell therapy company TCR2 Therapeutics...
...Inc. Aravive Inc. Editas Medicine Inc. Emalex Biosciences Inc. JMP Securities Melinta Therapeutics Inc. Molecular Partners AG Palladio Biosciences Inc. Santhera Pharmaceuticals Holding AG TCR2 Therapeutics Inc....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:HOTH) 2/15/19 $7.0 $52.8 $55.8 6% Stealth BioTherapeutics Corp. (NASDAQ:MITO) 2/14/19 $85.1 $420.4 $437.9 4% TCR2 Therapeutics Inc....
BioCentury | Jun 7, 2019
Finance

Alexandria parlays growing life sciences real estate holdings into a flurry of VC deals

...LLC in July 2018; the $125 million series B round for T cell therapy play TCR2 Therapeutics Inc....
...Precision BioSciences Inc., Durham, N.C. Relay Therapeutics Inc., Cambridge, Mass. Roche (SIX:ROG; OTCQB:RHHBY), Basel, Switzerland TCR2 Therapeutics Inc....
Items per page:
1 - 10 of 42